INS and type 2 diabetes mellitus: The analysis focuses on assessing the cost-effectiveness of IDegLira compared to other treatment regimens (liraglutide, degludec) for poorly controlled patients with type 2 diabetes who are currently receiving basic insulin therapy, from the perspective of a Chinese healthcare payer.